Jacques Lemmetti Appointed Chairman of the Board at Covalon.MISSISSAUGA, Ontario For the First Nation, see .
Mississauga (pronounced: [ˌmɪsɪˈsɑgə] -- Mr. Gary E. German, Chairman of Covalon Technologies Ltd. (Covalon) (TSX TSX Toronto Stock Exchange (TSE before April, 2002)
TSX Transfer from Stack Pointer to Index
TSX True Space Extension VENTURE:COV COV Composés Organiques Volatiles (French)
COV Compuestos Orgánicos Volátiles (Spanish: Volatile Organic Compounds)
COV Coefficient of Variation
COV City of Villians (game) ) is very pleased to announce that effective September 15, 2005, he will be succeeded as Chairman of the Board by Mr. Jacques M. Lemmetti.
Covalon Technologies has very successfully transitioned from a non-public entity developing proprietary products to now aggressively opening markets with multiple products and strategic industry franchise relationships. Mr. Lemmetti's vast experience in medical products and particularly in the advanced wound care field will help guide the company's future direction. Prior to accepting this new responsibility, Mr. Lemmetti served as president and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Hartmann-Conco, Inc. in the USA. There he transformed a commodity oriented company into an emerging player in the wound care arena. Previously, Mr. Lemmetti, acting as President, was the driving force behind the emergence of Smith & Nephew as one of the leading wound care companies in the USA. A Canadian expatriate, he has many years of experience in the Canadian market as well as significant exposure to the European market where he lived and directed a major medical products company. Mr. Lemmetti will contribute significantly to the Covalon team's strategy and effectiveness. The Board looks forward to receiving more of Jacques' time and industry knowledge both in the America's and Europe.
Mr. German will continue as a Director and Chair the Governance and Compensation committees.
Covalon Technologies Ltd. is a company with advanced medical products that has developed and patented advanced therapeutic biomaterials for wound care and surgical applications and coatings. Polymer chemistry Polymer chemistry or macromolecular chemistry is a multidisciplinary science that deals with the chemical synthesis and chemical properties of polymers or macromolecules. and surface coating technology have been combined to create a range of time-release drug delivery platforms that are applied to many medical devices to treat many critical conditions. A variety of applications for these technologies have been identified and specific products have been developed. The products offer features and benefits providing solutions to many of the problems caused by current devices and their material properties which are used by most medical device manufacturers and suppliers. The problems include infection, poor biocompatibility biocompatibility
the quality of not having toxic or injurious effects on biological systems.
biocompatibility 1. The extent to which a foreign, usually implanted, material elicits an immune or other response in a recipient 2. , and microbial microbial
pertaining to or emanating from a microbe.
the breakdown of organic material, especially feedstuffs, by microbial organisms. attachment.
The TSX Venture Exchange TSX Venture Exchange
Originally called the Canadian Venture Exchange (CDNX), this was a result of the merger of the Vancouver and Alberta stock exchanges. The goal of TSX Venture Exchange is to provide venture companies with effective access to capital while protecting investors. has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. The TSX Venture Exchange has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved of the contents of this release.
Covalon Technologies Ltd. (TSX VENTURE:COV)